Leukemia Cutis in a Patient with Acute Myeloid Leukemia Undergoing Azacitidine-Venetoclax: Case Presentation and Review of the Literature

被引：0

作者：

Buzzatti, Elisa ^{[1
]}

Mauro, Cristina ^{[1
]}

Botti, Caterina ^{[1
]}

Presicci, Roberta ^{[3
]}

Paterno, Giovangiacinto ^{[2
]}

Palmieri, Raffaele ^{[1
]}

Gurnari, Carmelo ^{[1
,4
]}

Mallegni, Flavia ^{[1
]}

Meddi, Elisa ^{[1
]}

Moretti, Federico ^{[1
]}

Cardillo, Lucia ^{[1
]}

Mezzanotte, Valeria ^{[1
]}

Taka, Kristian ^{[1
]}

De Marchi, Lucrezia ^{[1
]}

Maurillo, Luca

Buccisano, Francesco ^{[1
]}

Venditti, Adriano ^{[1
]}

del Principe, Maria Ilaria ^{[1
]}

机构：

[1] Univ Tor Vergata Rome, Dept Biomed & Prevent, Rome, Italy

[2] Policlin Tor Vergata, UOSD Mieloproliferat, Rome, Italy

[3] Univ Cagliari, Dept Med Sci & Publ Hlth, Cagliari, Italy

[4] Cleveland Clin, Taussig Canc Inst, Dept Translat Hematol & Oncol Res, Cleveland, OH USA

来源：

MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES | 2025年 / 17卷 / 01期

关键词：

Leukemia cutis; Acute myeloid leukemia; Demethylating agents; Venetoclax; NERVOUS-SYSTEM INVOLVEMENT; PROGNOSIS;

D O I：

10.4084/MJHID.2025.013

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Leukemia Cutis (LC) in acute myeloid leukemia (AML) is typically managed within the context of systemic AML therapy, namely intensive chemotherapy (IC). In frail patients, though, viable options are hypomethylating agents (HMAs) associated with Venetoclax (VEN), but data on the efficacy of this approach in this specific setting is scarce. Here, we report our experience and provide a short review of the previous cases of LC treated with HMAs plus VEN to underline the efficacy of such treatment in LC patients who are unsuitable for IC.

引用

页数：4

共 28 条

[1] A comparative study on demographic, hematological, and cytogenetic findings and prognosis in acute myeloid leukemia with and without leukemia cutis
Agis, H
Weltermann, A
Fonatsch, C
Haas, O
Mitterbauer, G
Müllauer, L
Schreiber, S
Schwarzinger, I
Juretzka, W
Valent, P
Jäger, U
Lechner, K
Geissler, K
[J]. ANNALS OF HEMATOLOGY, 2002, 81 (02) : 90 - 95
[2] How I treat extramedullary acute myeloid leukemia
Bakst, Richard L.
Tallman, Martin S.
Douer, Dan
Yahalom, Joachim
[J]. BLOOD, 2011, 118 (14) : 3785 - 3793
[3] Central Nervous System Involvement in Acute Myeloid Leukemia Patients Undergoing Hematopoietic Cell Transplantation
Bar, Merav
Tong, Weigang
Othus, Megan
Loeb, Keith R.
Estey, Elihu H.
[J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (03) : 546 - 551
[4] Venetoclax penetrates in cerebrospinal fluid of an acute myeloid leukemia patient with leptomeningeal involvement
Condorelli, Annalisa
Matteo, Cristina
Leotta, Salvatore
Schinina, Giovanni
Sciortino, Roberta
Piccolo, Gianna Maria
Parrinello, Nunziatina Laura
Proietto, Maria
Camuglia, Maria Grazia
Zucchetti, Massimo
Milone, Giuseppe
Di Raimondo, Francesco
[J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 89 (02) : 267 - 270
[5] The Venetoclax/Azacitidine Combination Targets the Disease Clone in Acute Myeloid Leukemia, Being Effective and Safe in a Patient with COVID-19
Cristiano, Antonio
Palmieri, Raffaele
Fabiani, Emiliano
Ottone, Tiziana
Divona, Mariadomenica
Savi, Arianna
Buccisano, Francesco
Maurillo, Luca
Tarella, Corrado
Arcese, William
Voso, Maria Teresa
[J]. MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2022, 14
[6] Complete eradication of chronic lymphocytic leukemia with unusual skin involvement of high mitotic index after time-limited venetoclax/obinutuzumab treatment
Dimou, Maria
Iliakis, Theodoros
Paradalis, Vasileios
Bitsani, Aikaterini
Kyrtsonis, Marie-Christine
Panayiotidis, Panayiotis
[J]. CLINICAL CASE REPORTS, 2021, 9 (07):
[7] Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
DiNardo, C. D.
Jonas, B. A.
Pullarkat, V.
Thirman, M. J.
Garcia, J. S.
Wei, A. H.
Konopleva, M.
Doehner, H.
Letai, A.
Fenaux, P.
Koller, E.
Havelange, V.
Leber, B.
Esteve, J.
Wang, J.
Pejsa, V.
Hajek, R.
Porkka, K.
Illes, A.
Lavie, D.
Lemoli, R. M.
Yamamoto, K.
Yoon, S. -S.
Jang, J. -H.
Yeh, S. -P.
Turgut, M.
Hong, W. -J.
Zhou, Y.
Potluri, J.
Pratz, K. W.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (07) : 617 - 629
[8] Extramedullary Involvement in Acute Myeloid Leukemia. A Single Center Ten Years' Experience
Fianchi, Luana
Quattrone, Martina
Criscuolo, Marianna
Bellesi, Silvia
Dragonetti, Giulia
Maraglino, Alessio Maria Edoardo
Bonanni, Matteo
Chiusolo, Patrizia
Sica, Simona
Pagano, Livio
[J]. MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2021, 13
[9] Cutaneous Leukemic Infiltrates Successfully Treated With Biomodulatory Therapy in a Rare Case of Therapy-Related High Risk MDS/AML
Heudobler, Daniel
Klobuch, Sebastian
Thomas, Simone
Hahn, Joachim
Herr, Wolfgang
Reichle, Albrecht
[J]. FRONTIERS IN PHARMACOLOGY, 2018, 9
[10] Simultaneous integrated boost with helical arc radiotherapy of total skin (HEARTS) to treat cutaneous manifestations of advanced, therapy-refractory cutaneous lymphoma and leukemia - dosimetry comparison of different regimens and clinical application
Hsieh, Chen-Hsi
Tien, Hui-Ju
Yu, Yuan-Bin
Wu, Yuan-Hung
Shueng, Pei-Wei
Lu, Yueh-Feng
Wang, Shan-Ying
Wang, Li-Ying
[J]. RADIATION ONCOLOGY, 2019, 14 (1)

← 1 2 3 →